Status:
UNKNOWN
Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCT
Lead Sponsor:
Hutchison Medipharma Limited
Conditions:
Advanced Malignant Solid Tumors
TGCT
Eligibility:
All Genders
18-75 years
Phase:
PHASE1
Brief Summary
To evaluate the safety and tolerability of HMPL-653 in patients with advanced solid tumors who have failure of standard of care or can not tolerate standard of care or those with TGCT, and to determin...
Eligibility Criteria
Inclusion
- Able to understand and willing to sign the ICF.
- Aged 18 to 75 years.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Life expectancy at least 12 weeks.
- Adequate bone marrow, liver and kidney function.
Exclusion
- Toxicity associated with previous antitumor therapy not recovered to ≤CTCAE grade 1；
- Previous treatment with anti-CSF1R therapy and have progressive disease;
- Receiving approved systematic antitumor therapy or in the treatment period of other interventional clinical study within 4 weeks prior to the first dose.
- Patients with central nervous system (CNS) malignant tumor or malignant solid tumor with known CNS metastasis;
- Pregnant or lactating women.
Key Trial Info
Start Date :
January 18 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 14 2025
Estimated Enrollment :
113 Patients enrolled
Trial Details
Trial ID
NCT05277454
Start Date
January 18 2022
End Date
April 14 2025
Last Update
March 14 2022
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Jilin Provincial Cancer Hospital
Changchun, China
2
Harbin Medical University Cancer Hospital
Harbin, China
3
Linyi Cancer Hospital
Linyi, China
4
Henan Cancer Hospital
Zhengzhou, China